Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ezerosu Single-layer vs Double-layer Tablet
NCT06225635Phase 1Completed
- Sponsor
- Shinpoong Pharma
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of ezetimibe and rosuvastatin in hyperlipidemia (2 arms), sponsored by Shinpoong Pharma. Primary endpoints: Maximum Plasma Concentration (Cmax) of Total Ezetimibe and Rosuvastatin at Day 8 and Area Under the Curve to the last measurable concentration (AUCt) of Total Ezetimibe and Rosuvastatin at Day 8. Started Jan 2022; status: completed.
02
Drugs
ezetimiberosuvastatin
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06225635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225635.